Loading…
BeOne Medicines AG is projected to rise to $398.44 by 2027, a +33% move from its current price of $298.70. ONC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $294.02 | $298.87 | $303.80 | +0.06% |
| Jul 14 | $292.20 | $299.04 | $306.03 | +0.11% |
| Jul 15 | $290.84 | $299.20 | $307.80 | +0.17% |
| Jul 16 | $289.74 | $299.37 | $309.33 | +0.22% |
| Jul 17 | $288.78 | $299.54 | $310.70 | +0.28% |
| Jul 18 | $287.94 | $299.71 | $311.96 | +0.34% |
| Jul 19 | $287.17 | $299.88 | $313.14 | +0.39% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $287.17 | $299.88 | $313.14 | +0.39% |
| Week 2 | $283.18 | $301.06 | $320.06 | +0.79% |
| Week 3 | $280.41 | $302.24 | $325.77 | +1.19% |
| Week 4 | $278.27 | $303.43 | $330.87 | +1.58% |
| Week 5 | $276.53 | $304.63 | $335.58 | +1.98% |
| Week 6 | $275.06 | $305.82 | $340.03 | +2.39% |
| Week 7 | $273.81 | $307.03 | $344.28 | +2.79% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BeOne Medicines AG is an oncology company that engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC.
It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd.
and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
BeOne Medicines AG (ONC) is a Swiss-based healthcare company focused on oncology, with a market cap of $30.09B and a current price near $289.99. It is ranked 434 by market capitalization among listed assets. The portfolio includes BRUKINSA, TEVIMBRA, SYLVANT, BAITUOWEI, and PARTRUVIX among its commercial stage products, along with a broad slate of clinical programs in various oncology modalities.
The forecast horizon presents a rising average price trajectory over time, with 2026 at $289.99 on average and substantial upside thereafter. The model projects average prices rising to $525.04 by 2030 and continuing to grow to $2,112.06 by 2050, with corresponding increases in projected ROI and bullish sentiment beyond 2026.
A major floor 19.6% below — a decisive break under it would weaken the trend.
The nearest floor, 12.9% below — buyers have tended to step in here.
The nearest ceiling, 3.6% above — a clean break opens room to run.
A major ceiling 13.4% above — clearing it would confirm fresh momentum.
Key ONC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ONC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $304.37 | Sell | $300.56 | Sell |
| MA 10 | $296.51 | Buy | $296.08 | Buy |
| MA 20 | $282.76 | Buy | $290.13 | Buy |
| MA 50 | $289.96 | Buy | $290.75 | Buy |
| MA 100 | $299.14 | Sell | $297.91 | Buy |
| MA 200 | $315.30 | Sell | $299.76 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.98 | Neutral |
| Stoch RSI (14) | 58.73 | Neutral |
| CCI (20) | 75.72 | Neutral |
| Williams %R (14) | -28.57 | Info |
| MACD (12,26,9) | 3.38 | Buy |
| ROC (12) | 8.17 | Buy |
| Bollinger %B (20,2) | 0.75 | Neutral |
| Stochastic %K (14) | 71.43 | Neutral |
| TRIX (15) | 0.07 | Buy |
| Awesome (5,34) | 20.78 | Buy |
| Ultimate (7,14,28) | 67.39 | Neutral |
| Momentum (10) | 23.36 | Buy |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 305.76 | Sell |
| ADX (14) | 21.38 | Buy |
| ATR (14) | 4.69 | Info |
The 30-day technical picture shows a neutral stance with room for a move. RSI(14) is 60, indicating balanced momentum. The 50-day simple moving average stands at $291.34, while the 200-day moving average sits at $316.66, suggesting the near-term average is modestly under broader trend lines.
Support is noted at $260.27 and resistance at $310.25, framing a near-term range that loosely tracks the 30-day low of $260.98 and high of $322.23. The stock shows about 30% annualized volatility, underscoring substantial but manageable swings around the current level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $260.27 | $298.70 | $402.74 | 0% | Neutral | |
| $326.33 | $398.44 | $508.62 | +33% | Bullish | |
| $392.23 | $487.91 | $639.68 | +63% | Bullish | |
| $437.37 | $552.45 | $739.71 | +85% | Bullish | |
| $471.01 | $602.97 | $821.91 | +102% | Bullish | |
| $482.60 | $625.35 | $865.90 | +109% | Bullish | |
| $532.33 | $697.60 | $979.67 | +134% | Bullish | |
| $621.22 | $822.66 | $1,170.26 | +175% | Bullish | |
| $708.28 | $947.28 | $1,363.64 | +217% | Bullish | |
| $782.27 | $1,056.13 | $1,537.26 | +254% | Bullish | |
| $1,125.12 | $1,584.32 | $2,416.66 | +430% | Bullish | |
| $1,892.28 | $2,857.77 | $4,672.66 | +857% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $260.27 | $298.70 | $357.99 | +0.00% |
| August 2026 | $267.68 | $313.31 | $374.66 | +4.89% |
| September 2026 | $267.31 | $314.39 | $378.88 | +0.34% |
| October 2026 | $265.45 | $313.49 | $380.30 | -0.29% |
| November 2026 | $271.99 | $322.33 | $393.19 | +2.82% |
| December 2026 | $276.29 | $328.48 | $402.74 | +1.91% |
Click any year to see its month-by-month ONC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ONC is projected to trade between $260.27 and $402.74, averaging $298.70 — a potential gain of 0% from today's $298.70. A consolidation phase looks the most probable path here.
BeOne Medicines AG's 2027 outlook centres on $398.44, within a $326.33 to $508.62 range. That is up +33% on the projected 2026 average. That marks a +33% change versus current levels. Momentum favours further upside here.
By 2028, ONC could reach as high as $639.68, with a base case around $487.91 and support toward $392.23 — roughly +63% from $298.70. Buyers look set to stay in control over this stretch.
Expect ONC to range from $437.37 to $739.71 through 2029. The $552.45 average target implies a +85% move from current prices. That is up +13% on the projected 2028 average. Momentum favours further upside here.
The ONC price prediction for 2030 points to an average of $602.97 (low $471.01, high $821.91) — a potential gain of +102% on today's $298.70. Buyers look set to stay in control over this stretch.
In 2031, ONC is projected to trade between $482.60 and $865.90, averaging $625.35 — a potential gain of +109% from today's $298.70. That is up +4% on the projected 2030 average. Momentum favours further upside here.
BeOne Medicines AG's 2032 outlook centres on $697.60, within a $532.33 to $979.67 range. That is up +12% on the projected 2031 average. That marks a +134% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, ONC could reach as high as $1,170.26, with a base case around $822.66 and support toward $621.22 — roughly +175% from $298.70. Momentum favours further upside here.
Expect ONC to range from $708.28 to $1,363.64 through 2034. The $947.28 average target implies a +217% move from current prices. That is up +15% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The ONC price prediction for 2035 points to an average of $1,056.13 (low $782.27, high $1,537.26) — a potential gain of +254% on today's $298.70. Momentum favours further upside here.
In 2040, ONC is projected to trade between $1,125.12 and $2,416.66, averaging $1,584.32 — a potential gain of +430% from today's $298.70. That is up +50% on the projected 2035 average. Buyers look set to stay in control over this stretch.
BeOne Medicines AG's 2050 outlook centres on $2,857.77, within a $1,892.28 to $4,672.66 range. That is up +80% on the projected 2040 average. That marks a +857% change versus current levels. Momentum favours further upside here.
Investing $1,000 in ONC today (≈ 3.347841 ONC) could be worth
$9,567.34
+$8,567.34 (+857%) by 2050 · US Dollar
Based on the average projected ONC price of $2,857.77 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ONCwould be worth at today's price.
$1,000 invested in ONC on Jul 10, 2025 (≈ 3.946486 ONC) would be worth
$1,178.82
+$178.82 (+17.9%) today · 1.18× · US Dollar
Based on a ONC entry price of $253.39 vs. today's $298.7.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $297.65 | $1,003.53 | +0.4% |
| 1 month ago | $263.61 | $1,133.11 | +13.3% |
| 3 months ago | $309.66 | $964.61 | -3.5% |
| 6 months ago | $333.99 | $894.34 | -10.6% |
| 1 year ago | $253.39 | $1,178.82 | +17.9% |
| All time (5.0y) ago | $330.35 | $904.19 | -9.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ONC forecast.
Our base-case forecast reaches $600.00 around 2030.
Implied market cap at $600.00: $56.94B
The multi-year forecast points to a bullish longer-term trajectory with rising average prices and expanding potential returns. In 2026, the average price is $289.99 with a neutral sentiment and a 0% ROI, while 2027 eyes an average of $366.73 and a 26.5% ROI in a bullish setup. From 2028 to 2030, the average price grows to $449.25, $525.04, and beyond, with ROIs of 54.9%, 81.1% respectively, indicating meaningful upside in the near term.
The forecast extends through 2031–2035 with continued gains and bullish sentiment, reaching an average of $849.76 by 2035 and ROI of 193%. By 2040 the average price is projected at $1,235.50 with a 326.1% ROI, and by 2050 the average price could reach $2,112.06 with a 628.3% ROI. Overall, the path implies a strong long-term bullish bias, though these are estimates and not guarantees, and individual outcomes will vary with market conditions and company progress.
Tap a question to reveal the answer.
The 2030 forecast shows min $409.96, average $525.04, max $716.08, ROI 81.1%, sentiment BULLISH.
The forecast portrays a bullish longer-term trajectory with rising average prices and ROI across multiple years, though the 2026 value is neutral and these are estimates, not guarantees.
In 2040 the min is $877.17, the average is $1,235.50, and the max is $1,885.09, with ROI 326.1% and bullish sentiment, indicating a path past $1,000 on the forecast horizon.
The 2050 max is $3,454.05, the average is $2,112.06, and the min is $1,398.21, with ROI 628.3% and bullish sentiment.
Current price $289.99; market cap $30.09B; rank 434.
BeOne Medicines AG Community Discussion
0Share your BeOne Medicines AG price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.